|
Peer-reviewed
Journal Publications
- Mitra
AP,
Bartsch CC, Bartsch
G Jr, Miranda G, Skinner EC, Daneshmand S. Does presence of squamous and
glandular differentiation in urothelial
carcinoma of the bladder at cystectomy portend poor prognosis? An
intensive case-control analysis. Urol Oncol, 2012. (in press)
- Ahmadi H, Mitra
AP, Abdelsayed GA, Cai
J, Djaladat H, Bruins HM, Daneshmand
S. Principal component analysis-based pre-cystectomy model to predict
pathologic stage in patients with clinical organ-confined bladder
cancer. BJU Int,
2012. (in press)
- Mitra
AP,
Castelao JE, Hawes D, Tsao-Wei
DD, Jiang X, Shi SR, Datar RH, Skinner EC,
Stein JP, Groshen S, Yu MC, Ross RK, Skinner
DG, Cortessis VK, Cote RJ. Combination of
molecular alterations and smoking intensity predicts bladder cancer
outcome: A report from the Los Angeles Cancer Surveillance Program. Cancer, 2012. (in press)
- Bruins
HM, Wopat R, Mitra AP, Cai J, Miranda G, Skinner EC, Daneshmand
S. Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following
partial cystectomy. BJU Int, 2012. (in
press)
- Mitra
AP,
Skinner EC, Miranda G, Daneshmand S. A
pre-cystectomy decision model to predict pathological upstaging and
oncological outcomes in clinical stage T2 bladder cancer. BJU Int,
2012. (in press)
- Mitra
AP,
Hansel DE, Cote RJ. Prognostic value of cell-cycle regulation biomarkers
in bladder cancer. Semin Oncol, 2012. (in press)
- Mitra
AP,
Jordà M, Cote RJ. Pathological possibilities
and pitfalls in detecting aggressive bladder cancer. Curr Opin Urol
22:397-404, 2012.
- Mitra
AP,
Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S. Factors influencing post-recurrence
survival in bladder cancer following radical cystectomy. BJU Int
109:846-854, 2012.
- Mitra
SA, Mitra AP, Triche TJ. A central role
for long non-coding RNA in cancer. Front
Gene 3:17, 2012.
- Mitra
AP,
Cote RJ. Molecular signatures that
predict nodal metastasis in bladder cancer: does the primary tumor tell
tales? Expert Rev Anticancer Ther 11:849-852, 2011.
- Kapur P, Lotan Y, King E, Kabbani
W, Mitra AP, Mosbah A, Abol-Enein H, Ghoniem M,
Youssef RF. Primary adenocarcinoma of the urinary bladder: value of cell
cycle biomarkers. Am J Clin Pathol 135:822-830, 2011.
- Bartsch G, Mitra
AP, Cote RJ. Expression profiling
for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther 10:1945-1954, 2010. [Cover feature]
- Mitra
AP,
Cote RJ. Molecular screening for
bladder cancer: progress and potential. Nature Rev Urol 7:11-20, 2010.
- Birkhahn M, Mitra
AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven
KE, Cote RJ. Predicting recurrence and progression of Ta bladder cancer
at initial presentation based on quantitative gene expression profiles. Eur Urol
57:12-20, 2010. [Platinum
Priority]
- Mitra
AP,
Bartsch CC, Cote
RJ. Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev 28:317-326,
2009.
- Mitra
AP,
Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen
S, Cote RJ. Generation of a concise gene panel for outcome prediction in
urinary bladder cancer. J Clin Oncol 27:3929-3937,
2009.
- Mitra
AP,
Cote RJ. Molecular pathogenesis and
diagnostics of bladder cancer. Annu Rev Pathol 4:251-285, 2009.
- Youssef
RF, Mitra AP, Bartsch G Jr,
Jones PA, Skinner DG, Cote RJ.
Molecular targets and targeted therapies in bladder cancer management. World J Urol
27:9-20, 2009.
- Pasin E,
Josephson DY, Mitra AP, Cote RJ,
Stein JP. Superficial bladder cancer: An update on etiology, molecular
development, classification, and natural history. Rev Urol 10:31-43, 2008.
- Birkhahn M, Mitra AP, Cote RJ. Molecular
markers for bladder cancer: the road to a multimarker
approach. Expert Rev Anticancer Ther 7:1717-1727, 2007. [Cover feature]
- Mitra
AP,
Birkhahn M, Cote
RJ. p53 and retinoblastoma pathways in bladder
cancer. World J Urol 25:563-571, 2007.
- Mitra
AP,
Cote RJ. Searching for novel
therapeutics and targets: Insights from clinical trials. Urol Oncol
25:341-343, 2007.
- Mitra AP,
Datar RH, Cote RJ. Molecular pathways in invasive bladder
cancer: New insights into mechanisms, progression, and target
identification. J Clin Oncol
24:5552-5564, 2006. [Cover
feature]
- Mitra
AP,
Lin H, Datar RH, Cote
RJ. Molecular biology of bladder cancer: Prognostic and clinical
implications. Clin Genitourin
Cancer 5:67-77, 2006. [Cover
feature]
- Mitra
AP,
Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP. The use of genetic programming in the
analysis of quantitative gene expression profiles for identification of
nodal status in bladder cancer. BMC
Cancer 6:159, 2006. [Highly
accessed]
- Mitra
AP,
Lin H, Cote RJ, Datar
RH. Biomarker profiling for cancer diagnosis, prognosis and therapeutic
management. Natl Med J India 18:304-312, 2005.
- Mitra AP,
Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int
96:7-12, 2005.
For
the most comprehensive and updated list of publications, please click here.
|
